We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitor... Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0337 | -4.71196868009 | 0.7152 | 0.7249 | 0.6371 | 107517 | 0.68964647 | CS |
4 | -0.0845 | -11.0313315927 | 0.766 | 0.8424 | 0.6 | 167171 | 0.73850774 | CS |
12 | 0.0766 | 12.663250124 | 0.6049 | 0.94 | 0.5612 | 234483 | 0.74198212 | CS |
26 | 0.0764 | 12.6260122294 | 0.6051 | 0.94 | 0.5 | 297571 | 0.67663735 | CS |
52 | -1.3185 | -65.925 | 2 | 3.7 | 0.5 | 363933 | 0.98899611 | CS |
156 | -5.1485 | -88.3104631218 | 5.83 | 16.41 | 0.5 | 276369 | 3.11504071 | CS |
260 | -15.0885 | -95.6785034876 | 15.77 | 17.99 | 0.5 | 244724 | 3.2877261 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions